Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Enzyme Inhibition

Enzyme Inhibition

Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.

Eukaryotic Transcription Inhibitors

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...

Receptor-mediated Endocytosis

Receptor-mediated Endocytosis

Receptor-mediated endocytosis is when bulk amounts of specific molecules are imported into a cell after binding to cell surface receptors. The molecules bound to these receptors are taken into the cell through inward folding of the cell surface membrane, which is eventually pinched off into a vesicle within the cell. Structural proteins, such as clathrin, coat the budding vesicle.
Clathrin-Mediated Endocytosis of LDL
One well-characterized example of receptor-mediated endocytosis is the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

[Development of peptidic MERS-CoV entry inhibitors].

Yao xue xue bao = Acta pharmaceutica Sinica·2016

Same author

[Small molecular agents against MERS-CoV infection].

Yao xue xue bao = Acta pharmaceutica Sinica·2016

Same author

Probing the Twisted Structure of Sickle Hemoglobin Fibers via Particle Simulations.

Biophysical journal·2016

Same author

Associations of THBS2 and THBS4 polymorphisms to gastric cancer in a Southeast Chinese population.

Cancer genetics·2016

Same author

De novo Transcriptome Analysis and Molecular Marker Development of Two Hemarthria Species.

Frontiers in plant science·2016

Same author

The Effectiveness of Transforaminal Versus Caudal Routes for Epidural Steroid Injections in Managing Lumbosacral Radicular Pain: A Systematic Review and Meta-Analysis.

Medicine·2016

Same journal

Mammalian Respiratory Chain Complex Assemblies and Their Links to Mitochondria Stress-Induced Human Diseases.

Advances in experimental medicine and biology·2026

Same journal

Enzyme Assemblies in Nucleotide Metabolism: Structure, Regulation, and Disease Implications.

Advances in experimental medicine and biology·2026

Same journal

The Pyruvate Dehydrogenase Complex: A 90-Year-Old Enigma Shaping the Future of Structural Enzymology.

Advances in experimental medicine and biology·2026

Same journal

Regulation of the Anti-termination RNA Transcription Complex by Lon-Mediated Lambda N Degradation.

Advances in experimental medicine and biology·2026

Same journal

PCNA Macromolecular Complexes: PCNA Serves as a Molecular Hub Regulating Multiple Cellular Processes Inside and Outside of the Nucleus.

Advances in experimental medicine and biology·2026

Same journal

Dynamic Assemblies in Genome Maintenance.

Advances in experimental medicine and biology·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Sep 27, 2025

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Published on: October 29, 2015

Coronavirus Entry Inhibitors.

Qiaoshuai Lan¹, Shuai Xia¹, Lu Lu²

¹Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences, Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, China.

Advances in Experimental Medicine and Biology

|April 12, 2022

Summary

This summary is machine-generated.

Developing coronavirus entry inhibitors is crucial for combating severe human coronavirus (HCoV) infections like COVID-19. These inhibitors target key steps in viral entry, offering a vital therapeutic strategy against dangerous HCoV strains.

Keywords:

Coronavirus Entry inhibitor Membrane fusion Proteolytic activation Receptor binding

More Related Videos

Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting

Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting

Published on: March 1, 2019

Visualization of SARS-CoV-2 using Immuno RNA-Fluorescence In Situ Hybridization

Visualization of SARS-CoV-2 using Immuno RNA-Fluorescence In Situ Hybridization

Published on: December 23, 2020

Related Experiment Videos

Last Updated: Sep 27, 2025

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Published on: October 29, 2015

Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting

Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting

Published on: March 1, 2019

Visualization of SARS-CoV-2 using Immuno RNA-Fluorescence In Situ Hybridization

Visualization of SARS-CoV-2 using Immuno RNA-Fluorescence In Situ Hybridization

Published on: December 23, 2020

Area of Science:

Virology
Infectious Diseases
Drug Development

Background:

Coronaviruses (CoVs) are widespread RNA viruses, with several human coronaviruses (HCoVs) causing significant illness.
Highly pathogenic HCoVs, including SARS-CoV-2, SARS-CoV, and MERS-CoV, pose severe health threats and can be fatal.
The ongoing COVID-19 pandemic underscores the urgent need for effective vaccines and antiviral agents against HCoVs.

Purpose of the Study:

To review and discuss the development of coronavirus entry inhibitors.
To highlight the role of entry inhibitors in combating HCoV infections.
To provide an overview of therapeutic strategies targeting viral entry mechanisms.

Main Methods:

Literature review and synthesis of existing research on coronavirus entry inhibitors.
Analysis of mechanisms by which entry inhibitors function.
Discussion of the therapeutic potential of entry inhibitors in treating coronavirus diseases.

Main Results:

Coronavirus entry inhibitors target critical stages of viral invasion, including receptor binding, spike protein activation, and membrane fusion.
These inhibitors demonstrate potential as standalone treatments or in combination therapies for coronavirus diseases.
The development of effective entry inhibitors is essential for managing HCoV outbreaks and pandemics.

Conclusions:

Coronavirus entry inhibitors represent a promising therapeutic avenue for preventing and treating infections caused by pathogenic human coronaviruses.
Targeting viral entry mechanisms is a key strategy in the development of novel anti-coronavirus drugs.
Continued research into coronavirus entry inhibitors is vital for global health security and pandemic preparedness.